Scancell

LSE: SCLP ↗$9.41 GBp~$50M (LSE, micro-cap) MCAP

#Cancer Vaccines #TCR Therapy #DNA Immunotherapy #Solid Tumors

Scancell Holdings plc (LSE: SCLP) is a clinical-stage immuno-oncology company developing novel cancer vaccines and T-cell receptor (TCR) therapies. Its lead asset, iSCIB1+, is a DNA-based cancer vaccine entering second-half 2026 clinical trials. Plans Nasdaq listing via reverse merger with Neuphoria.

Company Info

Sector:Cancer Immunotherapy

Headquarters:Oxford, UK

Founded:1996

Website:scancell.co.uk/

Scancell heads to Nasdaq via reverse merger with Neuphoria ↗

Scancell heads to Nasdaq via reverse merger with Neuphoria.

Leadership Team

Careers & Job Openings

See all open roles

Multiple Departments

UK - Oxford

Apply Now →